AI in Pharmacovigilance: Speed Without Shifting Responsibility
AI in pharmacovigilance has moved from proof of concept to production faster than almost any other regulated pharmaceutical workflow. Case volumes have grown for years while safety teams have not, and individual case processing is repetitive, text-heavy work that language models handle well. Companies now report automating large parts of intake, duplicate detection, coding, and narrative drafting, with intake to submission times falling sharply. The regulatory position has not softened in response. Joint principles from the United States and European agencies published early this year made the expectation explicit: AI in this setting must be explainable, traceable, and ready for inspection like any other regulated system.
Task by Task: What AI Does and Where It Fails
Automation is safest where the work is mechanical and riskiest where it is interpretive.
| Task | What AI Does Well | Failure Mode | Control |
|---|---|---|---|
| Case intake | Extracts fields from emails, forms, and calls | Misreads dates, doses, or free text | Field-level confidence and source linking |
| Duplicate detection | Matches cases across sources and spellings | Merges two genuinely different reports | Human confirmation before merging |
| Medical coding | Suggests terms consistently at volume | Plausible but incorrect term selection | Review of coded terms against source |
| Narrative drafting | Produces structured, readable summaries | Adds detail that is not in the source | Line-by-line verification against the case |
| Seriousness and causality | Little, this is judgement | Overstating or missing seriousness | Qualified assessment, always |
| Literature screening | Triages large volumes quickly | Silently missing a relevant article | Recall testing against known positives |
Where AI in Pharmacovigilance Genuinely Helps
The strongest case is throughput on structured work. Extracting case details from unstructured sources, matching duplicates across systems and languages, translating reports, suggesting coded terms, and drafting narratives are all tasks where volume has outgrown headcount. Faster intake matters clinically as well as commercially, because reporting clocks start the moment a case is received.
Why AI in Pharmacovigilance Scaled Before Other Regulated Work
Two conditions made this the first regulated area to automate heavily. The work is textual rather than physical, so a language model can do most of it, and volume grows with every product and every market while headcount does not. Add a reporting clock that starts the moment a case is received and the business case writes itself, which is why safety operations often moved faster than quality functions were comfortable with.
Signal detection benefits differently. Statistical methods on spontaneous report databases have existed for years. What AI adds is the ability to pull in messier sources, such as literature, call transcripts, and real-world data, and to surface candidate patterns earlier for human assessment. Earlier candidates are useful. They are not conclusions.
Why Judgement Remains the Hard Part
Deciding whether an event is serious, whether a case is valid, and whether a drug plausibly caused an outcome is medical judgement made under uncertainty. Models are poor at it and confident about it, which is the worst combination in safety work.
The specific failure that safety teams should test for is fabricated or amplified detail in narratives. A model summarising a sparse report can introduce a clinical detail that the reporter never provided, or characterise an event as serious when the source does not support it. Both directions are damaging. A false serious case consumes regulatory attention and can distort a signal. A missed one is worse. Unlike most AI errors, neither shows up as an obvious mistake, because the narrative reads exactly like a well-written case. Random sampling will not find them either, because the error rate concentrates in sparse or unusual reports rather than spreading evenly across the case load.
What Regulators Expect
Nothing in current expectations blocks AI in safety operations, and nothing removes existing obligations either. Qualified safety professionals remain responsible for case assessment before submission. The system producing or supporting those cases needs validation appropriate to its use, a documented context of use, and an audit trail that shows what the system did and who reviewed it. Vendor tools count as part of the regulated system, which makes contractual access to documentation and logs a compliance requirement rather than a nice-to-have.
Contracts matter more here than in most software purchases. If a vendor will not describe how its model was developed, will not share performance evidence, and will not provide access to logs, the sponsor still carries the obligation and simply cannot meet it. That question belongs in procurement, not in the first inspection.
This is the same discipline set out for computerised systems generally, which we covered in validating GenAI in pharma, and it now runs alongside the trial-side expectations described in AI in clinical trials. Inspections increasingly ask the same questions on both sides of the product lifecycle.
Seven Controls for a Safety System
These controls make an AI-assisted safety process defensible without slowing it down.
- Define the context of use per task. Intake extraction and causality assessment are different risk categories and need different controls.
- Link every field to its source. A reviewer should be able to see the sentence a value came from.
- Keep qualified review before submission. Automation can prepare a case, but a person is accountable for it.
- Test narrative fidelity deliberately. Sample cases specifically for detail that does not exist in the source.
- Measure recall, not just precision. In literature screening and signal work, what the system missed matters most.
- Version everything. Model, prompt, and vendor updates change behaviour and belong in change control.
- Keep an inspection-ready record. Inputs, outputs, reviewer identity, and timestamps for every case.
Cross-Check a Case Summary Across Six Models
Compare how six models read the same source report and flag the details only some of them see.
Try Talkory FreePros and Cons for Safety Teams
The operational benefit is real, and so is the new category of error it introduces.
- Pro: faster case processing. Intake to submission timelines shorten materially, which helps compliance with reporting clocks.
- Pro: consistency at volume. Coding and formatting decisions stop varying between individuals and shifts.
- Pro: broader source coverage. Literature, transcripts, and real-world data become searchable rather than sampled.
- Con: fabricated clinical detail. Narratives can gain specifics the source never contained.
- Con: silent misses. A screening system that drops a relevant article leaves no trace to investigate.
- Con: vendor opacity. Proprietary models complicate the documentation an inspection expects.
Real Scenarios Worth Thinking Through
These scenarios are illustrative, showing how AI in pharmacovigilance plays out in practice rather than presented as verified case studies.
A safety team deploys narrative drafting and reduces case turnaround substantially. During a quality review, several narratives are found to include a symptom that appears nowhere in the source report. The drafts were medically plausible, which is exactly why reviewers had stopped checking that particular field.
A literature screening model is tuned to reduce false positives, and the team celebrates a lower manual workload. Nobody measures recall against a set of known relevant articles until an inspection asks, at which point the missed cases are the finding.
A vendor updates its underlying model without notice. Coding suggestions shift, and the change is only noticed because the company tracks agreement rates between system suggestions and reviewer decisions over time. Without that metric, the drift would have been invisible.
Need Private Deployment for Safety Data?
Enterprise plans cover private deployment, custom data residency, dedicated infrastructure, and an SLA.
Talk to Enterprise Sales“After testing multiple AI models on coding, research, and business prompts, combined outputs produced more reliable results than any single model.” Internal multi-model evaluation, Talkory research team.
Why Talkory Wins
The dangerous errors in safety work are quiet ones: a detail added, a term chosen wrongly, an article missed. Talkory lets a team put the same source report in front of GPT, Claude, Gemini, Grok, Perplexity Sonar, and Kimi K3 and compare what each extracts. Where all six read the same events, doses, and dates, the extraction is probably faithful. Where one model produces a clinical detail the others do not, that detail is almost certainly not in the source. Used on a sample of cases, this becomes a practical fidelity test that quality teams can run without building an evaluation platform, and it pairs with the decision records described in our guide to the AI audit trail.
Final Verdict
AI in pharmacovigilance is one of the clearest wins available in regulated pharma operations, because the work is high volume, text-heavy, and growing. The obligations did not move. Keep qualified assessment on seriousness and causality, link every extracted field to its source, test narratives for invented detail, measure what your screening missed rather than only what it caught, and treat vendor models as part of your validated system. Faster cases are worth having. Faster cases nobody can defend at an inspection are not.
Frequently Asked Questions
Can AI process adverse event reports?
Yes. AI is widely used for case intake, duplicate detection, translation, medical coding suggestions, and narrative drafting. It handles the mechanical parts of individual case processing well, which is where most of the volume pressure sits.
Does a qualified person still need to review each case?
Regulatory expectations keep qualified safety professionals accountable for case assessment before submission. Automation can prepare and structure a case, but seriousness, validity, and causality judgements remain human decisions that must be documented.
What are the main risks of AI in drug safety?
Fabricated or amplified detail in narratives, incorrect coding that looks plausible, and silent misses in literature screening. All three are hard to spot because the output reads like competent work, which is why targeted sampling and recall testing matter.
How is AI validated for pharmacovigilance use?
Through the same principles applied to other regulated systems: a documented context of use, risk-proportionate performance evidence, change control covering model and prompt versions, an audit trail showing inputs, outputs, and reviewers, and access to vendor documentation.
Can AI detect safety signals on its own?
It can surface candidate patterns earlier and across messier sources than traditional methods, including literature and real-world data. Confirming a signal remains a medical and statistical judgement, and regulators expect that assessment to be made and documented by qualified staff.
Get 5 AI perspectives on this topic
Talkory runs your question through GPT, Claude, Gemini, Grok, Sonar & Kimi K3 simultaneously, then cross-checks the answers.